Health & Wellbeing | Michigan | Press AARP is hopeful a U.S. Supreme Court decision today will end pay-for-delay prescription drug agreements that cost consumers and taxpayers billions of dollars a year in Michigan and across the nation. Pay-for-delay agreements involve brand name and generic drug manufacturers entering into arrangements that pay the generic drug manufacturer to delay bringing its lower-priced alternative to market. This practice not only denies consumers access to lower-cost treatment options as soon as possible, but also prevents competition, said Joyce Rogers, AARP …